HUMA · Humacyte, Inc.
$0.60
+0.05 (+9.96%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will not have sufficient liquidity to fund our operations beyond one year from the issuance of these interim financial statements if we are unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$168.01M
Shares
277.80M
Humacyte, Inc. Earnings Call Transcripts
Every quarterly earnings call for Humacyte, Inc. (HUMA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$
−$31.90M
'24 Q1
24-05-10
·
$
−$56.66M
'24 Q2
24-08-13
·
$
−$39.20M
'24 Q3
24-11-08
·
$
−$20.94M
'24 Q4
25-03-28
·
$517,000
$39.14M
'25 Q1
25-05-13
·
$301,000
−$37.66M
'25 Q2
25-08-11
·
$753,000
−$17.51M
'25 Q3
25-11-12
·
$467,000
−$24.80M
'25 Q4
26-03-27
▼4.3%
$495,000
−$17.62M
'26 Q1
26-03-31
LATEST
▲34.9%
$406,000
−$36.80M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Humacyte, Inc. Q2 FY2026 Earnings Call
Confident tone
CTEV coronary program / IND
VO12 Phase III dialysis trial results
Supplemental BLA filing plans
Revenue
$406,000
▲ 34.9% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-03-31
Humacyte, Inc. Q1 FY2026 Earnings Call
Positive tone
CTEV in CABG (coronary program)
CMS reimbursement and female dialysis population
Supplemental BLA in dialysis
Revenue
$495,000
▼ 4.3% YoY Diluted EPS
$-0.09
▼ 132.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-27
Humacyte, Inc. Q4 FY2025 Earnings Call
Positive tone
Symvess U.S. commercial launch
International expansion
Clinical data and publications
Revenue
$467,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Humacyte, Inc. Q3 FY2025 Earnings Call
Positive tone
Symvess commercial launch and sales growth
Dialysis access program (ATEV/V007)
VAC committee approvals and hospital access expansion
Revenue
$753,000
Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Humacyte, Inc. Q2 FY2025 Earnings Call
Positive tone
Symvess commercial launch and VAC approvals
V007 Phase III dialysis / ATEV
Coronary artery bypass (CABG) program
Revenue
$301,000
Diluted EPS
$-0.24
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Humacyte, Inc. Q1 FY2025 Earnings Call
Confident tone
Symvess commercial launch and VAC approvals
ATEV dialysis access program (V007, V012, sBLA)
Small-diameter ATEV / coronary bypass program
Revenue
$517,000
Diluted EPS
$0.28
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-28
Humacyte, Inc. Q4 FY2024 Earnings Call
Confident tone
Symvess commercial launch and hospital adoption
Small diameter ATEV for CABG
ATEV dialysis access (V007/V012)
Revenue
$*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Humacyte, Inc. Q3 FY2024 Earnings Call
Positive tone
FDA BLA review of ATEV in vascular trauma
Biovascular Pancreas (BVP) for Type 1 diabetes
V007 Phase 3 dialysis access results
Revenue
$
Diluted EPS
$-0.33
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Humacyte, Inc. Q2 FY2024 Earnings Call
Positive tone
ATEV Phase 3 V007 dialysis access results
FDA review delay for vascular trauma BLA
Advanced Peripheral Arterial Disease (PAD) program
Revenue
$
Diluted EPS
$-0.48
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-10
Humacyte, Inc. Q1 FY2024 Earnings Call
Confident tone
BLA Review and FDA Interaction
Reimbursement and Coding
Dialysis Access / V007 Trial
Revenue
$
Diluted EPS
$-0.29
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-22
Humacyte, Inc. Q4 FY2023 Earnings Call
Confident tone
BLA submission and FDA acceptance for vascular trauma
Clinical data superiority vs. synthetic grafts
Commercial preparation and launch readiness
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Humacyte, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.25
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Humacyte, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.22
▼ 162.9% YoY
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Humacyte, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.36
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-24
Humacyte, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Humacyte, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.25
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
Humacyte, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$0.35
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-13
Humacyte, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.19
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
Humacyte, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–19 of 19 earnings calls
Key facts
CIK
1818382
CUSIP
44486Q103
13F (30d)
155 filings
152 filers
Visit website
Investor relations